Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioLineRx down 53% on end of BL-1020 CLARITY trial

This article was originally published in Scrip

Executive Summary

Israeli biopharma company BioLineRx saw its stock price cut by more than half on 20 March after the company said it would discontinue the Phase II/III CLARITY clinical trial for BL-1020 in the treatment of schizophrenia based on a planned interim analysis that showed the antipsychotic was not likely to meet the trial's primary efficacy endpoint.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020788

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel